E
Emilio Alba
Researcher at University of Málaga
Publications - 226
Citations - 6921
Emilio Alba is an academic researcher from University of Málaga. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 37, co-authored 197 publications receiving 5542 citations. Previous affiliations of Emilio Alba include Victoria University, Australia & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Kimberly L. Blackwell,Fabrice Andre,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Katarína Petráková,Lowell L. Hart,Cristian Villanueva,A. Chan,Erik Jakobsen,Arnd Nusch,Olga Burdaeva,Eva-Maria Grischke,Emilio Alba,Erik Wist,Norbert Marschner,Anne Favret,Denise A. Yardley,Thomas Bachelot,Ling-Ming Tseng,Sibel Blau,Fengjuan Xuan,Farida Souami,Michelle Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +36 more
TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
Journal ArticleDOI
Missing data imputation using statistical and machine learning methods in a real breast cancer problem
José M. Jerez,Ignacio Molina,Pedro J. García-Laencina,Emilio Alba,Nuria Ribelles,Miguel Martín,Leonardo Franco +6 more
TL;DR: The method based on machine learning techniques were the most suited for the imputation of missing values and led to a significant enhancement of prognosis accuracy compared to imputation methods based on statistical procedures.
Journal ArticleDOI
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
Roy R. L. Bastien,Álvaro Rodríguez-Lescure,Mark T. W. Ebbert,Aleix Prat,Aleix Prat,Blanca Munárriz,Leslie R. Rowe,Patricia Miller,Manuel Ruiz-Borrego,Daniel Anderson,Bradley W. Lyons,Isabel Alvarez,Tracy Dowell,David Wall,Miguel Ángel Seguí,Lee Barley,Kenneth M. Boucher,Emilio Alba,Lisa Pappas,Carole Davis,Ignacio Aranda,Christiane Fauron,Inge J. Stijleman,José Palacios,Antonio Antón,Eva Carrasco,Rosalía Caballero,Matthew J. Ellis,Torsten O. Nielsen,Charles M. Perou,Mark E. Astill,Philip S. Bernard,Philip S. Bernard,Miguel Martin +33 more
TL;DR: The standard immunohistochemical panel for breast cancer (ER, PR, and HER2) does not adequately identify the PAM50 gene expression subtypes and single gene scoring for ESR1, PGR, and ERBB2 was more prognostic than the corresponding IHC markers as shown in a multivariate analysis.
Journal ArticleDOI
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
Miguel Martin,Álvaro Rodríguez-Lescure,Amparo Ruiz,Emilio Alba,Lourdes Calvo,Manuel Ruiz-Borrego,Blanca Munárriz,César A. Rodríguez,C. Crespo,Enrique de Alava,José Antonio López García-Asenjo,María Dolores Guitián,Sergio Almenar,Jesús Fernando González-Palacios,Francisco Vera,José Palacios,Manuel Ramos,Jose Manuel Gracia Marco,Ana Lluch,Isabel Alvarez,Miguel Ángel Seguí,Jose I. Mayordomo,Antonio Antón,J. M. Baena,Arrate Plazaola,Alfonso Modolell,Amadeu Pelegrí,J. R. Mel,Enrique Aranda,Encarna Adrover,José Valero Álvarez,José Luis García Puche,Pedro Sánchez-Rovira,Sonia González,J. M. López-Vega +34 more
TL;DR: Among patients with operable breast cancer, FEC-P treatment statistically significantly reduced the risk of relapse compared with FEC as adjuvant therapy and no statistically significant interaction between HER2 status and paclitaxel treatment was found.
Journal ArticleDOI
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer
Miguel Martin,Miguel Ángel Seguí,Antonio Antón,Amparo Ruiz,Manuel Ramos,Encarna Adrover,Ignacio Aranda,Álvaro Rodríguez-Lescure,Regina Große,Lourdes Calvo,Agustí Barnadas,Dolores Isla,Purificación Martínez del Prado,Manuel Ruiz Borrego,J. Zaluski,A. Arcusa,Montserrat Muñoz,José M. López Vega,J. R. Mel,Blanca Munárriz,Cristina Llorca,Carlos Jara,Emilio Alba,J. Florián,Junfang Li,José Antonio López García-Asenjo,Amparo Sáez,María José Rios,Sergio Almenar,Gloria Peiró,Ana Lluch +30 more
TL;DR: Adjuvant TAC improved the rate of disease-free survival among women with high-risk, node-negative breast cancer and was consistent, regardless of hormone-receptor status, menopausal status, or number of high- risk factors.